Final Results

Summary by AI BETAClose X

Diaceutics PLC reported strong financial results for FY 2025, with revenue growing 24% on a constant currency basis to £38.4 million and adjusted EBITDA increasing 80% to £7.6 million, marking a return to profitability. The company ended the year with a record order book of £38.9 million and Annual Recurring Revenue (ARR) of £20.0 million, providing good visibility for continued growth in 2026. The number of customer therapeutic brands working with Diaceutics increased by 12% to 95, and two additional top 10 global pharma companies became enterprise-wide engagement customers. A second PMx commercialization partnership was signed in Q4, and the company noted that AI is further enhancing data processing and insight generation. Trading in Q1 2026 has been in line with board expectations.

Disclaimer*

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings